Esperoct Market Report 2026

Esperoct Market Overview

• The Esperoct market growth in the historic period has been driven by high bleeding risk in hemophilia a patients, dependence on frequent factor viii infusions • Market expansion is supported by increasing adoption of extended half-life therapies, expansion of homecare treatment models • Growth Driver: Rising Incidence Of Bleeding Disorders Driving Growth In The Esperoct Market • Market Trend: Regulatory Approvals Driving Global Expansion Of Esperoct In Hemophilia A Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Esperoct Market?

Esperoct (efanesoctocog alfa) is a long-acting recombinant factor VIII therapy designed to treat hemophilia A by replacing the missing clotting factor and preventing bleeding episodes. Its extended formulation reduces the need for frequent infusions, enhancing patient convenience and quality of life. The main types of treatments in esperoct are prophylaxis and on-demand treatment. Prophylaxis refers to the action or measures taken to prevent the onset of disease or health issues. It includes various clinical indications, such as routine prophylaxis, perioperative management, and expanded age use, and caters to various end users, including hospitals, specialty clinics, and homecare settings.

What Is The Esperoct Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption of extended half-life therapies, expansion of homecare treatment models, rising hemophilia diagnosis rates, improved patient adherence, supportive reimbursement for rare diseases. Major trends in the forecast period include long-acting clotting factor therapies, shift toward prophylactic hemophilia care, reduced infusion frequency treatments, improved quality of life in hemophilia, expansion of home infusion programs.

Global Esperoct Market Segmentation

1) By Treatment Type: Prophylaxis, On-Demand Treatment 2) By Clinical Indication: Routine Prophylaxis, Perioperative Management, Expanded Age Use 3) By End-User: Hospitals, Specialty Clinics, Homecare Settings

What Are The Drivers Of The Esperoct Market?

The growing incidence of bleeding disorders is expected to propel the growth of the esperoct market going forward. Bleeding disorders refer to a group of medical conditions that impair the blood's ability to clot properly, leading to excessive or prolonged bleeding. The growing incidence of bleeding disorders can be due to improved diagnosis, increased awareness, genetic factors, and the aging population, which may lead to a higher recognition and detection of these conditions. Esperoct is used to treat bleeding disorders, specifically hemophilia A, by replacing the missing clotting factor VIII, which helps prevent or control bleeding episodes in patients with this condition. For instance, in May 2025, according to Pfizer, a US-based biopharmaceutical corporation, in the UK, the haemophilia A and B patient population exceeded 11,800 individuals in the 2023/2024 period. Therefore, the growing incidence of bleeding disorders is driving the growth of the esperoct industry. The rising health care investments are expected to propel the growth of the esperoct market going forward. Healthcare investments refer to the allocation of financial resources into the healthcare sector, including funding for healthcare facilities, technologies, pharmaceutical companies, medical research, and other related services. Rising healthcare investments are driven by the increasing demand for advanced medical technologies, an aging population, growing healthcare needs, and the push for innovations in treatments, pharmaceuticals, and disease prevention. Esperoct is utilized in healthcare investments by offering a therapeutic solution for hemophilia A, driving investments in the development of innovative treatments, expanding access to specialized care, and improving patient outcomes through advanced biotechnology. For instance, in November 2024, according to the Health Foundation, a UK-based independent charity, planned healthcare spending is set to increase from around $221.1 billion (£177.9 billion) to $237.4 billion (£190.1 billion) in 2024/25 and further rise to $250.1 billion (£200.5 billion) in 2025/26. Therefore, the rising health care investments are driving the growth of the esperoct industry.

Key Players In The Global Esperoct Market

Major companies operating in the esperoct market are Novo Nordisk A/S

Global Esperoct Market Trends and Insights

A key trend in the esperoct market is gaining regulatory approvals to expand its accessibility in various global markets. Regulatory approvals refer to the official authorization granted by government agencies, such as the FDA or EMA, allowing a drug or medical product to be legally marketed and sold in a specific region or country after confirming its safety, efficacy, and quality. For instance, in October 2023, the Therapeutic Goods Administration (TGA), an Australia-based government agency, approved Esperoct (turoctocog alfa pegol) as a new biological entity for the treatment of hemophilia A. This medication is indicated for routine prophylaxis to prevent bleeding episodes, on-demand treatment for bleeding, and perioperative management. Esperoct works by temporarily correcting factor VIII deficiency, which is crucial for managing this serious bleeding disorder. The approval followed a thorough evaluation of its quality, safety, and efficacy, and it is also monitored under Australia's Black Triangle Scheme to enhance pharmacovigilance for newly authorized medicines.

Regional Insights

North America was the largest region in the esperoct market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Esperoct Market?

The esperoct market consists of sales of products including octocog alfa, kovaltry, recombinant factor VIII. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Esperoct Market Report 2026?

The esperoct market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the esperoct industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.